MTL-004, a promising new therapeutic for post-resection treatment of glioblastoma

Autors:

Mike Hudson, Elisabeth Bertrand, Sylvie Maubant, Marie Lux, Elodie Marie Dit Chatel, Jordan Longin, Sophie Chaumeron, Maxime Beauchet,Anne-Pascale Luzy, Pauline Bornert, Olivier Duchamp

Oncodesign Services, Gordian Pharma LTD

Abstract :

Objectives:
Glioblastomas (GBM), are exceptionally hard to treat, aggressive and genetically heterogeneous tumors. We report the tolerance, biodistribution and excretion ofMTL-004 (5-(aziridine-1- yl)-4 hydroxylamino-2-nitrobenzamide) in healthy animals, along with data its effect when delivered as a single intra-cranial dose in a bioresorbable paste (poly DL-lactic acid-co-glycolic acid and poly ethylene glycol (PGLA/PEG)) following surgical resection of primary GBM, on tumor growth and survival.

Conclusions
MTL-004 was found to be safe and well-tolerated at a dose of 1 mg/kg, and was excreted mainly through urine. Following resection, PO TMZ seemed to have a transient impact on tumor growth, but minimal survival gains compared to placebo. In contrast, a single IC treatment with MTL-004 in paste provided prolonged control of tumor recurrence leading to a significantly increased survival of animals.

Download the Poster >>